Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.

Revvity (RVTY) shares advanced Monday after the medical equipment maker formerly known as PerkinElmer posted better-than-expected results and boosted its profit guidance on higher demand for its diagnostic products.

Revvity, Inc. (NYSE:RVTY ) Q2 2024 Earnings Conference Call July 29, 2024 8:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President & CEO Max Krakowiak - SVP & CFO Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Catherine Schulte - Baird Luke Sergott - Barclays Michael Ryskin - Bank of America Paul Knight - KeyBanc Rachel Vatnsdal - JP Morgan Tycho Peterson - Jefferies Operator Hello, and welcome to the Q2 2024 Revvity Earnings Conference Call. My name is Elliott, and I'll be coordinating your call today.

The headline numbers for Revvity (RVTY) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Medical equipment maker Revvity raised its annual profit forecast on Monday, after beating second-quarter results estimates on better-than-expected demand for its diagnostic products.

Revvity (RVTY) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.21 per share a year ago.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 30, 2024. The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a year ago. GAAP revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $86 million, as compared to $78 million for the same period a year ago. GAAP op.

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflow VIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has entered into a software marketing agreement with Revvity, Inc. (NYSE: RVTY) under which Revvity will market and commercialize Bionano's VIA™ software as part their newborn sequencing research workflow. VIA is expected to enhance the comprehensive reporting capabilities of Revvity's sequencing solution by adding an assessment of CNVs to its NGS workflow and streamlining the workflow's interpretation capabilities.

Revvity's (RVTY) strong product portfolio raises optimism about the stock.